Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
11 02 2020
Historique:
received: 22 04 2019
pubmed: 10 9 2019
medline: 17 12 2020
entrez: 10 9 2019
Statut: ppublish

Résumé

In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was to provide characterization of incident cancer types. All incident cases of cancer occurring in IBD patients from December 2011-2017 were prospectively recorded in 16 Italian Group for the Study of Inflammatory Bowel Disease units. Each of the IBD patients with a new diagnosis of cancer was matched with 2 IBD patients without cancer, according to IBD phenotype (ulcerative colitis [UC] vs Crohn's disease [CD]), age (±5 years), sex. Risk factors were assessed by multivariate logistic regression analysis. Cancer occurred in 403 IBD patients: 204 CD (CD cases), 199 UC (UC cases). The study population included 1209 patients (403 IBD cases, 806 IBD controls). Cancer (n = 403) more frequently involved the digestive system (DS; 32%), followed by skin (14.9%), urinary tract (9.7%), lung (6.9%), genital tract (6.5%), breast (5.5%), thyroid (1.9%), lymphoma (2.7%, only in CD), adenocarcinoma of the small bowel (SBA; 3.9%, 15 CD, 1 pouch in UC), other cancers (15.9%). Among cancers of the DS, colorectal cancer (CRC) more frequently occurred in UC (29% vs 17%; P < 0.005), whereas SBA more frequently occurred in CD (13% vs 6.3% P = 0.039). In CD, perforating (B3) vs non-stricturing non-perforating (B1) behavior represented the only risk factor for any cancer (odds ratio [OR], 2.33; 95% confidence interval [CI], 1.33-4.11). In CD, risk factors for extracolonic cancer (ECC) were a B3 vs B1 and a stricturing (B2) vs B1 behavior (OR, 2.95; 95% CI, 1.62-5.43; OR, 1.79; 95% CI, 1.09-2.98). In UC, risk factors for ECC and for overall cancer were abdominal surgery for UC (OR, 4.63; 95% CI, 2.62-8.42; OR, 3.34; 95% CI, 1.88-5.92) and extensive vs distal UC (OR, 1.73; 95% CI, 1.10-2.75; OR, 1.99; 95% CI, 1.16-3.47). Another risk factor for ECC was left-sided vs distal UC (OR, 1.68; 95% CI, 1.00-2.86). Inflammatory bowel disease duration was a risk factor for skin and urinary tract cancers. Perforating CD, extensive UC, and abdominal surgery for UC were identified as risk factors for overall incident cancer and for ECC. The clinical characteristics associated with severe IBD may increase cancer risk.

Sections du résumé

BACKGROUND
In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was to provide characterization of incident cancer types.
METHODS
All incident cases of cancer occurring in IBD patients from December 2011-2017 were prospectively recorded in 16 Italian Group for the Study of Inflammatory Bowel Disease units. Each of the IBD patients with a new diagnosis of cancer was matched with 2 IBD patients without cancer, according to IBD phenotype (ulcerative colitis [UC] vs Crohn's disease [CD]), age (±5 years), sex. Risk factors were assessed by multivariate logistic regression analysis.
RESULTS
Cancer occurred in 403 IBD patients: 204 CD (CD cases), 199 UC (UC cases). The study population included 1209 patients (403 IBD cases, 806 IBD controls). Cancer (n = 403) more frequently involved the digestive system (DS; 32%), followed by skin (14.9%), urinary tract (9.7%), lung (6.9%), genital tract (6.5%), breast (5.5%), thyroid (1.9%), lymphoma (2.7%, only in CD), adenocarcinoma of the small bowel (SBA; 3.9%, 15 CD, 1 pouch in UC), other cancers (15.9%). Among cancers of the DS, colorectal cancer (CRC) more frequently occurred in UC (29% vs 17%; P < 0.005), whereas SBA more frequently occurred in CD (13% vs 6.3% P = 0.039). In CD, perforating (B3) vs non-stricturing non-perforating (B1) behavior represented the only risk factor for any cancer (odds ratio [OR], 2.33; 95% confidence interval [CI], 1.33-4.11). In CD, risk factors for extracolonic cancer (ECC) were a B3 vs B1 and a stricturing (B2) vs B1 behavior (OR, 2.95; 95% CI, 1.62-5.43; OR, 1.79; 95% CI, 1.09-2.98). In UC, risk factors for ECC and for overall cancer were abdominal surgery for UC (OR, 4.63; 95% CI, 2.62-8.42; OR, 3.34; 95% CI, 1.88-5.92) and extensive vs distal UC (OR, 1.73; 95% CI, 1.10-2.75; OR, 1.99; 95% CI, 1.16-3.47). Another risk factor for ECC was left-sided vs distal UC (OR, 1.68; 95% CI, 1.00-2.86). Inflammatory bowel disease duration was a risk factor for skin and urinary tract cancers.
CONCLUSIONS
Perforating CD, extensive UC, and abdominal surgery for UC were identified as risk factors for overall incident cancer and for ECC. The clinical characteristics associated with severe IBD may increase cancer risk.

Identifiants

pubmed: 31498388
pii: 5536256
doi: 10.1093/ibd/izz155
doi:

Substances chimiques

Immunologic Factors 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

450-459

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Livia Biancone (L)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Alessandro Armuzzi (A)

IBD Unit, Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.

Maria Lia Scribano (ML)

GI Unit, AO S. Camillo Forlanini, Rome, Italy.

Fabiana Castiglione (F)

Università Federico II, Naples, Italy.

Renata D'Incà (R)

IBD Unit, Gastroenterology, Azienda-Università of Padova, Padua, Italy.

Ambrogio Orlando (A)

IBD Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Claudio Papi (C)

IBD Unit, S. Filippo Neri Hospital, Rome, Italy.

Marco Daperno (M)

AO Ordine Mauriziano, SC Gastroenterologia, Turin, Italy.

Maurizio Vecchi (M)

University of Milan, IRCCS Ca' Granda, Ospedale Maggiore Policlinico Foundation, Milan, Italy.

Gabriele Riegler (G)

Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.

Walter Fries (W)

IBD Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Patrizia Alvisi (P)

GI Unit, AUSL Bologna, Bologna, Italy.

Gianmichele Meucci (G)

GI Unit, San Giuseppe Hospital, Milan, Italy.

Filippo Mocciaro (F)

GI and Endoscopy Unit, ARNAS Civico Di Cristina-Benfratelli, Palermo, Italy.

Francesca Rogai (F)

AOU Careggi, Firenze, Italy.

Stefano Festa (S)

IBD Unit, S. Filippo Neri Hospital, Rome, Italy.

Luisa Guidi (L)

IBD Unit, Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy.

Anna Testa (A)

Università Federico II, Naples, Italy.

Luisa Spina (L)

IRCCS Policlinico S. Donato, Milan, Italy.

Sara Renna (S)

IBD Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Anna Viola (A)

IBD Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Marta Patturelli (M)

Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.

Roberto Di Mitri (R)

GI and Endoscopy Unit, ARNAS Civico Di Cristina-Benfratelli, Palermo, Italy.

Iris Frankovic (I)

IBD Unit, Gastroenterology, Azienda-Università of Padova, Padua, Italy.

Emma Calabrese (E)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Carmelina Petruzziello (C)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Elena De Cristofaro (E)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Giorgia Sena (G)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Alessandra Ruffa (A)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Benedetto Neri (B)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Alessandra Rossi (A)

Department of Systems Medicine, GI Unit, Università degli Studi di Roma "Tor Vergata", Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH